Pfizer Declares First-Quarter 2025 Dividend
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/7/2026
- Nasdaq futures fall after record Samsung profit fails to calm AI chip worries
- Oil gains after vessel attacks near Strait of Hormuz
- Citi says SpaceX stock has path to $900+ valuation. Here’s how
- Tesla stock target lifted at RBC on potential SpaceX merger
- Short squeezes more likely than widespread selling: Citi
- Rivian Automotive (RIVN) files for 75M share offering
- Rivian offers Q2 2026 revenue outlook, cash position grows
- Nokia OYJ (NOKIA:FH) (NOK) PT Raised to EUR14 at Kepler Cheuvreux
- Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
- Coursera plans layoffs after Udemy merger, estimates $8M-$11M in costs
Goldman Sachs Reiterates Buy Rating on Pfizer (PFE)
December 16, 2024 4:14 AM ESTGoldman Sachs analyst Chris Shibutani reiterated a Buy rating and $33.00 price target on Pfizer (NYSE: PFE).
The analyst comments "Ahead of PFE's 2025 Guidance call (Tuesday, December 17) we outline our expectations for the guide and commentary on the upcoming year. Overall, we anticipate that PFE management will guide to earnings (EPS) in the mid-to-high $2 range with core business growth offset by... More
